by Bhaswati Guha Majumder - Jun 5, 2021 08:45 AM
Bharat Biotechâs COVAXIN
As India is looking forward to World Health Organizationâs (WHO) approval for Hyderabad based Bharat Biotechâs Covaxin jab, the Center said that âthe milestone will be achieved soonâ.
During a news conference on the Covid-19 situation in India, Dr VK Paul, Member (Health) Niti Aayog, said that the authorities have been working with Bharat Biotech and WHO, data exchange is underway and we are keen that this milestone is accomplished soon.
Meanwhile, on 4 June, Anvisa, which is Brazil s health agency, approved imports of Russia s Sputnik V as well as India s Covaxin (BBV152 COVID-19) vaccinationsâbut with conditions on both the jabs.
Several men at the village in Rajasthan's Tonk district believed that vaccination against Covid-19 could led to impotency or 'losing their manhood' as some stated.
A recent study reveals that Pfizer s vaccine against COVID-19 is less effective against coronavirus, but it gives protection against more variants of the virus first found in India. The study was conducted by France s Pasteur Institute. The study collected samples from 28 healthcare workers in the city of Orleans. COVID-19 Vaccine Update: Pfizer s Coronavirus Vaccine Less Effective But Still Gives Protection Against B.1.617 Variant, Reveals Study.
Comments
Johnson and Johnson on Tuesday, 20 April, said that it will resume roll-out of its single-shot COVID-19 vaccine in Europe after the European Union’s drug regulator announced that blood clots were a very rare side effect of the vaccine and “its benefits outweigh the risk”.
The European Medicines Agency (EMA) has recommended a warning should be added to the vaccine’s product information.
“Healthcare professionals and people who receive the vaccine should be aware of the possibility of very rare cases of blood clots combined with low levels of blood platelets occurring within three weeks of vaccination,” stated the EMA.
Vaccine for all above 18 from May 1: Key highlights of govt s Phase 3 strategy
Under the Phase 3 vaccination policy, vaccine makers will supply 50 per cent of their doses to the Centre and the remaining 50 per cent to states and in the open market
BusinessToday.In | April 20, 2021 | Updated 08:28 IST
Vaccination will continue as before in government vaccination centres
In a crucial decision in the battle against Covid-19, a meeting of all high-level officials, top experts and ministers led by Prime Minister Narendra Modi decided to allow vaccination to all above the age of 18 from May 1. The new vaccination rule will help India vaccinate at a record pace, he said. The industry as well as common people have cheered the government s decision, which will majorly impact the rising coronavirus tally in India.